DexCom Inc. ($DXCM) Stock Forecast: Up 5.3% Today

What is DexCom Inc.?

DexCom (DXCM) is a leading glucose monitor manufacturer that has been gaining attention for its innovative products and strong financial performance in the market. The company recently experienced positive movement in its stock price, driven by impressive preliminary Q4 results and an optimistic outlook for 2026.

Why is DexCom Inc. going up?

DXCM stock is up 5.3% on Jan 12, 2026 18:55

• DexCom's stock had a notable bullish trend, propelled by robust preliminary Q4 results that surpassed revenue expectations and demonstrated significant growth in both domestic and international markets.
• The introduction of DexCom's G7 15-Day sensor and the FDA approval for Smart Basal technology have been key factors in fostering positive market sentiment, revealing a high demand for the company's advanced products.
• Analysts at Morgan Stanley maintained an Overweight rating for DexCom, pointing to the strong Q4 results and the appointment of a new CEO as favorable catalysts for the company's future growth.
• While there are varied analyst opinions on DexCom's valuation, the general market sentiment remains optimistic, with investors looking forward to the company's sustained revenue growth, enhanced margins, and expansion strategies for 2026.

DXCM Price Chart

DXCM Technical Analysis

DXCM News

DexCom stock holds Overweight rating at Morgan Stanley on solid Q4 results

Morgan Stanley reiterated an Overweight rating and $75.00 price target for DexCom following the company's strong preliminary Q4 2025 results, which exceeded consensus estimates for both U.S. and international revenue. DexCom also provided conservative 2026 guidance, projecting total revenue between $5.16 billion and $5.25 billion with improved adjusted gross and operating margins. Recent developments for DexCom include new CEO Jake Leach, FDA clearance for Smart Basal technology, and updated analyst targets from Leerink Partners and Raymond James.

https://www.investing.com/news/analyst-ratings/dexcom-stock-holds-overweight-rating-at-morgan-stanley-on-solid-q4-results-93CH-4442625

iRhythm Technologies stock maintains Overweight rating at Morgan Stanley

Morgan Stanley has maintained an Overweight rating and $205.00 price target on iRhythm Technologies (NASDAQ:IRTC) following strong preliminary fourth-quarter results, which exceeded consensus revenue estimates. The company reported robust year-over-year revenue growth and provided an optimistic outlook for fiscal year 2026, surpassing Street estimates, despite not yet expecting profitability this year. The forecast also does not include potential revenue from its next-generation Mobile Cardiac Telemetry device, which awaits FDA clearance and could significantly increase market share.

https://www.investing.com/news/analyst-ratings/irhythm-technologies-stock-maintains-overweight-rating-at-morgan-stanley-93CH-4442503

Glucose monitor maker Dexcom's prelim Q4 revenue beats expectations on G7 15 Day launch

Dexcom, a glucose monitor manufacturer, announced preliminary fourth-quarter revenue that surpassed expectations. This positive performance is attributed to the recent launch of its G7 15-Day sensor. The article is a brief headline-only report from Reuters.

https://www.tradingview.com/news/reuters.com,2026:newsml_L1N3YD0ED:0-glucose-monitor-maker-dexcom-s-prelim-q4-revenue-beats-expectations-on-g7-15-day-launch/

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

Dexcom, Inc. reported strong preliminary, unaudited financial results for the fourth quarter and full fiscal year 2025, with total revenue exceeding guidance and significant growth in both domestic and international markets. The company also provided a positive outlook for 2026, anticipating continued revenue growth and favorable non-GAAP gross profit and operating margins, driven by increased CGM awareness, the rollout of Stelo, and international expansion. Dexcom plans to release its audited full results on February 12, 2026.

https://www.businesswire.com/news/home/20260112293861/en/Dexcom-Reports-Preliminary-Unaudited-Results-for-the-Fourth-Quarter-and-Fiscal-Year-2025-and-Initial-2026-Outlook

Assessing DexCom (DXCM) Valuation As Analyst Actions And Conference Spotlight Shape Sentiment

DexCom (DXCM) is drawing attention due to its presentation at the J.P. Morgan Healthcare Conference and mixed analyst ratings. While a "Most Popular Narrative" suggests DexCom is 21% undervalued with a fair value of $85, another view based on discounted cash flow points to a richer price, implying shares are expensive at $53.26. The article highlights that the fair value is sensitive to assumptions about revenue growth, profit margins, and potential risks like Medicare bidding pressures and product quality issues.

https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/assessing-dexcom-dxcm-valuation-as-analyst-actions-and-confe

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.1% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Down 5.1% Today

Monero ($XMR) Crypto Forecast: Down 8.7% Today

Chainlink ($LINK) Crypto Forecast: Down 5.1% Today

Apache Corporation ($APA) Stock Forecast: Down 5.3% Today

Devon Energy Corporation ($DVN) Stock Forecast: Down 5.2% Today

Goldman Sachs Group Inc. (The) ($GS) Stock Forecast: Up 5.0% Today

Cardano ($ADA) Crypto Forecast: Down 5.5% Today

United Continental Holdings Inc. ($UAL) Stock Forecast: Up 5.0% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 6.0% Today

DexCom Inc. Price History

05.00.2026 - DXCM Stock was up 2.8%

• The bullish movement in DXCM stock today can be attributed to the company's position at an inflection point in the competitive glucose-monitoring market, with positive sentiment from analysts on its future prospects.
• Recent insider transactions, including some purchases at lower prices, suggest continued long-term confidence in DXCM despite short-term valuation concerns, contributing to the positive momentum.
• The company's innovative products and favorable regulatory environment are likely driving investor optimism and contributing to the stock's strong performance in today's trading session.

10.11.2025 - DXCM Stock was up 4.1%

• The rise in DXCM's stock price could be linked to investors potentially seeing recent class action lawsuits and allegations as temporary hurdles that DexCom can navigate.
• Despite legal concerns regarding unauthorized design alterations to its devices and resulting reliability and health issues, investors may have confidence in DexCom's ability to tackle these challenges and uphold its market position.
• Investor faith in DXCM may also be bolstered by positive updates or announcements regarding the company's product pipeline, partnerships, or financial performance, overshadowing the short-term legal uncertainties.
• Overall, today's bullish movement in DXCM's stock suggests that investors are concentrating on the company's long-term growth potential and resilience in the face of legal obstacles, rather than solely dwelling on the ongoing lawsuits and allegations.

11.10.2025 - DXCM Stock was up 5.7%

• The rise in DXCM's stock value may stem from investors perceiving the recent securities fraud class action lawsuits as temporary obstacles that DexCom will likely surmount.
• Despite the legal hurdles, investor confidence in DexCom's capacity to innovate within the healthcare technology industry could be bolstering the stock's performance.
• Growing interest in the stock might also be a result of speculation surrounding potential resolutions or settlements related to the securities law violations, fostering a positive outlook among traders.

12.00.2026 - DXCM Stock was up 5.3%

• DexCom's stock had a notable bullish trend, propelled by robust preliminary Q4 results that surpassed revenue expectations and demonstrated significant growth in both domestic and international markets.
• The introduction of DexCom's G7 15-Day sensor and the FDA approval for Smart Basal technology have been key factors in fostering positive market sentiment, revealing a high demand for the company's advanced products.
• Analysts at Morgan Stanley maintained an Overweight rating for DexCom, pointing to the strong Q4 results and the appointment of a new CEO as favorable catalysts for the company's future growth.
• While there are varied analyst opinions on DexCom's valuation, the general market sentiment remains optimistic, with investors looking forward to the company's sustained revenue growth, enhanced margins, and expansion strategies for 2026.

11.10.2025 - DXCM Stock was up 5.1%

• Today's bullish movement in DXCM's stock may be linked to the favorable market response to its robust Q3 growth and expanded CGM coverage, positioning the company for ongoing adoption despite growing competition.
• Despite facing legal challenges such as securities fraud class action lawsuits and allegations of securities law violations, investors appear to be more focused on the company's growth potential and momentum driven by innovation.
• While some investors have taken a bearish stance in the options market, this sentiment does not seem to have significantly impacted DXCM's stock performance today, as the overall optimistic outlook on the company's future prospects overshadowed these issues.

12.00.2026 - DXCM Stock was up 5.1%

• Dexcom experienced a strong bullish movement recently due to several positive factors:
• The fourth-quarter revenue surpassed expectations, mainly due to the successful launch of the G7 15-Day sensor, showcasing the company's innovation and responsiveness to market needs.
• The appointment of a new President and CEO, Jake Leach, coupled with plans to introduce an AI-enabled Stelo app, reflects a strategic shift towards advanced technology in diabetes management.
• Analysts have expressed optimistic views on Dexcom's performance for 2026, projecting revenue growth and improved margins, which has boosted investor confidence and generated a bullish sentiment.
• Despite concerns raised by some analysts about weaker gross margins and potential pricing pressures, Dexcom's proactive approach to product development and leadership changes has outweighed these worries, leading to an increase in the stock price.

13.10.2025 - DXCM Stock was up 5.1%

• An upcoming lead plaintiff deadline in a securities lawsuit may have initially caused volatility in the stock.
• Despite bearish opinions in the options market, positive news surrounding DXCM's strong growth in Q3 and focus on innovation likely reassured investors and supported the bullish movement.
• Ongoing securities fraud class action lawsuits and legal reminders could have led to short-term fluctuations. However, the overall positive view on DXCM's performance and market position has been more prominent, driving the bullish trend.
• Investors appear to be placing more emphasis on the company's growth potential and competitive standing rather than its legal challenges, leading to an increase in the stock price.

06.00.2026 - DXCM Stock was up 5.1%

• The bullish movement in DXCM stock today can be attributed to the unveiling of a new app feature by a competitor aimed at enhancing mealtime decisions for individuals with diabetes. This innovation in the diabetes management space may have positively influenced investor sentiment towards DexCom.
• The market may also be reacting to the detailed overview of DexCom's stock performance and financial data, showcasing its fundamental strength and role in continuous glucose monitoring systems.
• Additionally, the nuanced view on Dexcom's valuation and long-term growth prospects from top institutional shareholders and recent insider trades might have instilled confidence in investors, contributing to the bullish momentum.

07.10.2025 - DXCM Stock was down 5.1%

• The decrease in DXCM stock value might be linked to legal actions taken against the company alleging securities fraud, which has caused uncertainty among investors.
• Despite reporting strong double-digit growth in Q3 earnings and increasing its projected revenue for 2025, the stock price dropped, potentially indicating that the legal issues have overshadowed the positive financial performance.
• Investor sentiment towards DXCM appears pessimistic, possibly driven by worries concerning the lawsuits' impact on the company's image and long-term growth prospects.

31.09.2025 - DXCM Stock was down 15.0%

• Despite surpassing earnings and revenue estimates in Q3, DexCom's stock experienced a bearish movement possibly due to ongoing securities class action lawsuits.
• Investor uncertainty may have increased as investigations into potential breaches of fiduciary duties by certain officers and directors were revealed, further impacting confidence in the company.
• Analysts initially highlighted positive earnings growth potential, but the overshadowing legal issues and declining short interest may have contributed to the bearish market movement today.

31.09.2025 - DXCM Stock was down 13.7%

• The filing of class action lawsuits against DexCom Inc. by multiple law firms likely influenced the stock's bearish performance.
• Despite exceeding Q3 earnings and revenue expectations, legal issues facing the company may have dampened the impact of positive financial results.
• The decline in short interest may suggest a waning confidence or increased uncertainty among investors about the company's future trajectory.
• Legal disputes and uncertainties surrounding DexCom Inc. might have eroded investor trust, contributing to the bearish trend witnessed in the market today.

31.09.2025 - DXCM Stock was down 14.3%

• Despite strong growth in Q3 and an increase in revenue projections for 2025, DXCM saw a decline in its stock price, signaling a disconnect between its performance and investor expectations.
• An ongoing examination into potential breaches of fiduciary duties by certain company officials could have contributed to investor unease and the stock's bearish performance.
• Legal actions initiated by a law firm on behalf of DXCM investors within a specific timeframe might have added to the negative market sentiment surrounding the company.
• Even surpassing Q3 earnings and revenue forecasts may not have been enough to counterbalance overarching market apprehensions and legal uncertainties, resulting in the decline in the stock's value.